Yet, the initial ND6 increase as reported by us for SS, confirmed for Type 2 diabetes patients (22), followed by a decrease in ND6 expression when progressing to MeSH (8), would fit the proposed compensation model of dynamic regulation as a response to mitochondrial dysfunction during disease progression (10, 11, 14). This evidence concerns the gene MT-ND6 and type 2 diabetes mellitus.